1. Topalian, S. L. (1994) MHC class II restricted tumor antigens and the role of CD4+ T-cells in cancer immunotherapy. Curr. Opin. Immunol. 6, 741–745.
2. Southwood, S., Sidney, J., Kondo, A., del Guercio, M. F., Appella, E., Hoffman, S., Kubo, R. T., Chesnut, R. W., Grey, H. M., and Sette, A. (1998) Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160, 3363–3373.
3. Sinigaglia, F. and Hammer, J. (1994) Defining rules for the peptide-MHC class II interaction. Curr. Opin. Immunol. 6, 52–56.
4. Sette, A., Adorini, L., Colon, S. M., Buus, S., and Grey, H. M. (1989) Capacity of intact proteins to bind to MHC class II molecules. J. Immunol. 143, 1265–1267.
5. Stern, L. J., Brown, J. H., Jardetzky, T. S., Gorga, J. C., Urban, R. G., Strominger, J. L., and Wiley, D. C. (1994) Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368, 215–221.